First in Human Study of TORL-1-23 in Participants With Advanced Cancer

NCT05103683 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Ovarian Cancer
Endometrial Cancer
NSCLC

Interventions

DRUG: TORL-1-23

Sponsor

TORL Biotherapeutics, LLC

Collaborators

[object Object]